Objectives: Convulsive status epilepticus is a medical emergency. Prompt treatment has been shown to decrease progression to refractory convulsive status epilepticus. We aimed to reduce time to second-line anti-seizure medication through implementation of a standardized treatment protocol. Design: Quality improvement project. We constructed a multidisciplinary team and completed Plan-Do-Study-Act cycles to achieve the project aim. Setting: A tertiary care children’s hospital. Patients: Patients presenting to the Children’s Hospital at Montefiore emergency department with convulsive status epilepticus or new-onset seizures during admission to Children’s Hospital at Montefiore. Interventions: Implementation of a standardized treatment protocol, uploading the protocol to the hospital’s intranet, adding anti-seizure medications to the hospital’s Pyxis system, and creating a standardized convulsive status epilepticus order set in the electronic medical record. The primary outcome measure was time from order to administration of second-line anti-seizure medication, and secondary outcome was total seizure time. Measurements and Main Results: Seventy-eight patients were analyzed, including 41 from the baseline period (January 2014 through June 2015) and 37 from the postintervention period (July 2015 through December 2016). The median time to administration of second-line anti-seizure medication decreased from 52 to 21 minutes (p = 0.001) and total seizure time from 65 to 31 minutes (p = 0.09). Conclusions: A standardized treatment protocol for convulsive status epilepticus decreased time to administration of second-line therapy by 60%, but there was no statistically significant decrease in total seizure time. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (https://ift.tt/2gIrZ5Y). The authors have disclosed that they do not have any potential conflicts of interest. For information regarding this article, E-mail: gcassel@montefiore.org ©2018The Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
from Emergency Medicine via xlomafota13 on Inoreader https://ift.tt/2KmAFwX
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Ravulizumab (ravulizumab-cwvz; ULTOMIRIS™), a humanized monoclonal antibody, is a complement C5 inhibitor developed by Alexion Ph...
-
http://bit.ly/2TO0eLw
-
Training in teamwork behaviour improves technical resuscitation performance. However, its effect on patient outcome is less clear, partly be...
-
Abstract Objective Long-acting synthetic somatostatin analogues (SSA) are an essential part of the treatment of neuroendocrine neoplasms...
-
Medicine by Alexandros G. Sfakianakis BioMed Research International BioMed Research InternationalTanshinone IIA Alleviates CCL2-Induced Le...
-
Abstract Chronic venous disease (CVD) is both prevalent and unavoidable in many people as a result of persistent or unalterable risk facto...
-
Abstract Chronic low-grade inflammation is now widely accepted as one of the most important contributors to metabolic disorders. Glycoprot...
-
Medicine by Alexandros G. Sfakianakis Atmosphere, Vol. 11, Pages 876: The Distribution... Behavioural Brain ResearchAcute serotonin 2A r...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου